IOVA – iovance biotherapeutics, inc. (US:NASDAQ)

News

Iovance Biotherapeutics (IOVA) had its price target raised by Barclays PLC from $10.00 to $11.00. They now have an "overweight" rating on the stock.
Iovance Biotherapeutics (IOVA) had its price target lowered by Chardan Capital from $17.00 to $16.00. They now have a "buy" rating on the stock.
Iovance Biotherapeutics Inc (IOVA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Iovance Biotherapeutics (IOVA) was upgraded by Citizens Jmp from "market perform" to "outperform". They now have a $5.00 price target on the stock.
Iovance Biotherapeutics, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com